June 20, 2022— Members of the U.S. House of Representatives from both political parties went to the House floor recently to deliver a historic series of speeches honoring the upcoming 30th anniversary of the 340B drug pricing program and urging their colleagues to defend the program against unlawful attacks by drug companies. The lawmakers’ unified message was that 340B is … [Read more...]
Bipartisan Congressional Calls to Protect 340B Intensify
Aug. 4, 2021– A pair of lawmakers is working to advance the latest example of bipartisan, pro-340B legislation in Congress. Reps. Abigail Spanberger (D-Va.) and David McKinley (R-W.V.) recently introduced the Preserving Rules Ordered for The Entities Covered Through 340B Act, also known as the PROTECT 340B Act, and are gathering cosponsors from both sides of the political … [Read more...]
More States Acting To Protect 340B Safety-Net Hospitals
May 12, 2021– Faced with increasing threats from some pharmaceutical benefit managers (PBMs) and drug companies, supporters of the 340B drug pricing program have turned to state governments for protection and are finding increasing support in the form of new protective laws thanks to the work of 340B advocates in the states. To date, 11 states have enacted important … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]
Senate Hearing Next Week on Outrageous Prescription Drug Prices
December 5, 2017—The Senate Health, Education, Labor and Pensions (HELP) Committee is holding a Dec. 12 hearing on new National Academies of Sciences (NAS) findings on why medicines cost so much and recommendations on how to fix the problem. The NAS’s Nov. 30 report is drawing attention for calling on the federal government to negotiate drugs prices with manufacturers, deny … [Read more...]